Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 19/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17494033 | 0.82 | AAK1 (0.77) | AAK1TAAR1 | |
| SCHEMBL17494046 | 0.81 | AAK1 (1.00) | AAK1TAAR1 | |
| SCHEMBL17493870 | 0.81 | AAK1 (0.81) | AAK1TAAR1 | |
| Hydrochloric Acid SCHEMBL19328169 | 0.80 | AAK1 (0.80) | AAK1TAAR1 | |
| SCHEMBL17516047 | 0.79 | AAK1 (0.84) | AAK1TAAR1 | |
| SCHEMBL17516056 | 0.74 | AAK1 (0.83) | AAK1TAAR1 | |
| SCHEMBL17494011 | 0.74 | AAK1 (0.92) | AAK1 | |
| SCHEMBL17493959 | 0.73 | AAK1 (0.92) | AAK1TAAR1 | |
| SCHEMBL17493893 | 0.72 | AAK1 (0.82) | AAK1TAAR1 | |
| SCHEMBL17494071 | 0.72 | AAK1 (0.92) | AAK1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | claimed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | claimed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| WO-2016022312-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | AAK1, NCK1, DAPK2 | AAK1 1/4885TAAR1 3583/4885 |
| US-10035777-B2 | Heterocyclic kinase inhibitors | AAK1, NCK1, DAPK2 | AAK1 1/4885TAAR1 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.